ABEO Long Put Strategy
ABEO (Abeona Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO (Abeona Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $325.7M, a trailing P/E of 4.89, a beta of 1.34 versus the broader market, a 52-week range of 4-7.54, average daily share volume of 1.2M, a public-listing history dating back to 1980, approximately 136 full-time employees. These structural characteristics shape how ABEO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.34 indicates ABEO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 4.89 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a long put on ABEO?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current ABEO snapshot
As of May 15, 2026, spot at $5.53, ATM IV 115.20%, IV rank 29.35%, expected move 33.03%. The long put on ABEO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long put structure on ABEO specifically: ABEO IV at 115.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABEO long put, with a market-implied 1-standard-deviation move of approximately 33.03% (roughly $1.83 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABEO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABEO should anchor to the underlying notional of $5.53 per share and to the trader's directional view on ABEO stock.
ABEO long put setup
The ABEO long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABEO near $5.53, the first option leg uses a $5.53 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABEO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABEO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $5.53 | N/A |
ABEO long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
ABEO long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on ABEO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on ABEO
Long puts on ABEO hedge an existing long ABEO stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ABEO exposure being hedged.
ABEO thesis for this long put
The market-implied 1-standard-deviation range for ABEO extends from approximately $3.70 on the downside to $7.36 on the upside. A ABEO long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long ABEO position with one put per 100 shares held. Current ABEO IV rank near 29.35% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABEO at 115.20%. As a Healthcare name, ABEO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABEO-specific events.
ABEO long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABEO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABEO alongside the broader basket even when ABEO-specific fundamentals are unchanged. Long-premium structures like a long put on ABEO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ABEO chain quotes before placing a trade.
Frequently asked questions
- What is a long put on ABEO?
- A long put on ABEO is the long put strategy applied to ABEO (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With ABEO stock trading near $5.53, the strikes shown on this page are snapped to the nearest listed ABEO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABEO long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the ABEO long put priced from the end-of-day chain at a 30-day expiry (ATM IV 115.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABEO long put?
- The breakeven for the ABEO long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABEO market-implied 1-standard-deviation expected move is approximately 33.03%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on ABEO?
- Long puts on ABEO hedge an existing long ABEO stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ABEO exposure being hedged.
- How does current ABEO implied volatility affect this long put?
- ABEO ATM IV is at 115.20% with IV rank near 29.35%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.